Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director · President, R&D · 10% owner | September 04, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date September 04, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,302,145 |
Ending reported balance
After 2026-09-04 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2026-09-04 · Sale · Disposed 520 · Balance 1,326,625 F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 2 · 2026-09-04 · Sale · Disposed 2,006 · Balance 1,324,619 F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 3 · 2026-09-04 · Sale · Disposed 3,267 · Balance 1,321,352 F5: The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 4 · 2026-09-04 · Sale · Disposed 3,962 · Balance 1,317,390 F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 5 · 2026-09-04 · Sale · Disposed 3,180 · Balance 1,314,210 F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 6 · 2026-09-04 · Sale · Disposed 3,392 · Balance 1,310,818 F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 7 · 2026-09-04 · Sale · Disposed 2,320 · Balance 1,308,498 F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 8 · 2026-09-04 · Sale · Disposed 1,242 · Balance 1,307,256 F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 9 · 2026-09-04 · Sale · Disposed 1,992 · Balance 1,305,264 F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 10 · 2026-09-04 · Sale · Disposed 565 · Balance 1,304,699 F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 11 · 2026-09-04 · Sale · Disposed 1,329 · Balance 1,303,370 F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 12 · 2026-09-04 · Sale · Disposed 826 · Balance 1,302,544 F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 13 · 2026-09-04 · Sale · Disposed 399 · Balance 1,302,145 F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Spousal Trust | 90,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 90,000 F16: Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Suma Mani Krishnan Trust | 51,010 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 51,010 F17: Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Family Trust | 50,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 50,000 F18: Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5: The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F16: Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee.
F17: Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust.
F18: Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2023 Filed Apr 18, 2023 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 500 | $89.12 | $44,558.75 |
DisclosureSEC source: 0001298711-23-000012 · wf-form4_168184848206201.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,713,688 F7 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan. F8 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F6 · price: The transaction was executed in multiple trades ranging from $89.0650 to $89.2300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F9 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 9,724 | $88.41 | $859,661.89 |
DisclosureSEC source: 0001298711-23-000012 · wf-form4_168184848206201.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,714,188 F7 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan. F8 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F5 · price: The transaction was executed in multiple trades ranging from $88.0500 to $89.0100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F9 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 9,428 | $87.41 | $824,113.74 |
DisclosureSEC source: 0001298711-23-000012 · wf-form4_168184848206201.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,723,912 F7 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan. F8 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F4 · price: The transaction was executed in multiple trades ranging from $87.0500 to $88.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F9 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,298 | $86.80 | $373,050.93 |
DisclosureSEC source: 0001298711-23-000012 · wf-form4_168184848206201.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,733,340 F7 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan. F8 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F3 · price: The transaction was executed in multiple trades ranging from $86.0500 to $87.0450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F9 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,050 | $85.55 | $89,825.72 |
DisclosureSEC source: 0001298711-23-000012 · wf-form4_168184848206201.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,737,638 F7 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan. F8 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F2 · price: The transaction was executed in multiple trades ranging from $85.0500 to $86.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F9 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 500 | $89.12 | $44,558.75 |
DisclosureSEC source: 0001298711-23-000012 · wf-form4_168184848206201.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,649,206 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan. F6 · price: The transaction was executed in multiple trades ranging from $89.0650 to $89.2300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 9,724 | $88.41 | $859,661.89 |
DisclosureSEC source: 0001298711-23-000012 · wf-form4_168184848206201.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,649,706 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan. F5 · price: The transaction was executed in multiple trades ranging from $88.0500 to $89.0100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 9,429 | $87.41 | $824,202.09 |
DisclosureSEC source: 0001298711-23-000012 · wf-form4_168184848206201.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,659,430 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan. F4 · price: The transaction was executed in multiple trades ranging from $87.0500 to $88.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,297 | $86.80 | $372,964.13 |
DisclosureSEC source: 0001298711-23-000012 · wf-form4_168184848206201.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,668,859 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan. F3 · price: The transaction was executed in multiple trades ranging from $86.0500 to $87.0450. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,050 | $85.55 | $89,826.14 |
DisclosureSEC source: 0001298711-23-000012 · wf-form4_168184848206201.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,673,156 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and contemplated quarterly sales of 25,000 shares with a limit price of $80.00 per share. The Rule 10b5-1 trading plan has now reached the maximum number of shares to be sold under such plan. F2 · price: The transaction was executed in multiple trades ranging from $85.0500 to $86.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 28, 2023 Filed Feb 28, 2023 23:41 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantPerformance Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-23-000010 · wf-form4_167762766195597.xml · derivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F6 · derivative.exercise_price: Each performance stock unit ("PSU") represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain corporate performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. F7 · shares: The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance criteria set by the Company's Compensation Committee for this award. F8 · derivative.exercise_date: If any applicable portion of the performance criteria have been achieved, the award shall vest in two equal annual installments (February 28, 2024 and February 28, 2025). F9 · derivative.expiration_date: If the performance criteria are not achieved, the portion of the award which was capable of vesting on that date will expire. F7 · derivative.underlying_shares: The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance criteria set by the Company's Compensation Committee for this award. F7 · balance_after: The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance criteria set by the Company's Compensation Committee for this award. Read SEC document |
| February 28, 2023 Filed Feb 28, 2023 23:41 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $81.91 | $0.00 |
DisclosureSEC source: 0001298711-23-000010 · wf-form4_167762766195597.xml · derivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-02-28 F5 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 28, 2024. Read SEC document |
| February 26, 2023 Filed Feb 28, 2023 23:41 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 3,057 | $78.46 | $239,852.22 |
DisclosureSEC source: 0001298711-23-000010 · wf-form4_167762766195597.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,674,206 F1 · shares: Represents tax withholding upon the vesting of 7,100 shares of restricted stock on February 26, 2023. F2 · price: The closing price on February 24, 2023 of the Company's common stock on NASDAQ. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 22:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 803 | $81.56 | $65,492.04 |
DisclosureSEC source: 0001298711-23-000006 · wf-form4_167416827258921.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,738,688 F5 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F9 · price: The transaction was executed in multiple trades ranging from $81.3700 to $81.9200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F7 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 22:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,048 | $80.75 | $165,382.35 |
DisclosureSEC source: 0001298711-23-000006 · wf-form4_167416827258921.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,739,491 F5 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F8 · price: The transaction was executed in multiple trades ranging from $80.3500 to $81.3300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F7 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 22:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 804 | $81.56 | $65,573.60 |
DisclosureSEC source: 0001298711-23-000006 · wf-form4_167416827258921.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,677,263 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F9 · price: The transaction was executed in multiple trades ranging from $81.3700 to $81.9200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 18, 2023 Filed Jan 19, 2023 22:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,048 | $80.75 | $165,381.53 |
DisclosureSEC source: 0001298711-23-000006 · wf-form4_167416827258921.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,678,067 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F8 · price: The transaction was executed in multiple trades ranging from $80.3500 to $81.3300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 346 | $82.71 | $28,619.18 |
DisclosureSEC source: 0001298711-23-000006 · wf-form4_167416827258921.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,741,539 F5 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F4 · price: The transaction was executed in multiple trades ranging from $82.3300 to $83.2500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F7 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,186 | $81.41 | $96,547.75 |
DisclosureSEC source: 0001298711-23-000006 · wf-form4_167416827258921.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,741,885 F5 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F3 · price: The transaction was executed in multiple trades ranging from $81.1300 to $82.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F7 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 20,617 | $80.70 | $1,663,831.07 |
DisclosureSEC source: 0001298711-23-000006 · wf-form4_167416827258921.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,743,071 F5 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F2 · price: The transaction was executed in multiple trades ranging from $80.1300 to $81.1000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F7 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 345 | $82.72 | $28,536.78 |
DisclosureSEC source: 0001298711-23-000006 · wf-form4_167416827258921.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,680,115 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F4 · price: The transaction was executed in multiple trades ranging from $82.3300 to $83.2500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,186 | $81.41 | $96,548.35 |
DisclosureSEC source: 0001298711-23-000006 · wf-form4_167416827258921.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,680,460 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F3 · price: The transaction was executed in multiple trades ranging from $81.1300 to $82.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 20,617 | $80.70 | $1,663,831.07 |
DisclosureSEC source: 0001298711-23-000006 · wf-form4_167416827258921.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,681,646 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $80.1300 to $81.1000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 23:10 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,748 | $80.08 | $300,140.21 |
DisclosureSEC source: 0001298711-23-000004 · wf-form4_167296023235886.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,763,688 F3 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F2 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.5000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F5 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 23:10 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,938 | $80.09 | $315,384.97 |
DisclosureSEC source: 0001298711-23-000004 · wf-form4_167296023235886.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,702,263 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.5000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 23:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,700 | $80.33 | $136,566.95 |
DisclosureSEC source: 0001298711-23-000002 · wf-form4_167278944683523.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,767,436 F4 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F5 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F10 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F7 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the reporting person. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 23:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,700 | $80.33 | $136,554.20 |
DisclosureSEC source: 0001298711-23-000002 · wf-form4_167278944683523.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,706,201 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F9 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.6700. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 23:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 563 | $81.11 | $45,662.40 |
DisclosureSEC source: 0001298711-23-000002 · wf-form4_167278944683523.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,769,136 F4 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F5 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F8 · price: The transaction was executed in multiple trades ranging from $81.0000 to $81.2700. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F7 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the reporting person. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 23:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 7,447 | $80.28 | $597,848.88 |
DisclosureSEC source: 0001298711-23-000002 · wf-form4_167278944683523.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,769,699 F4 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F5 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F6 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.9900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F7 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the reporting person. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 23:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 528 | $81.10 | $42,821.86 |
DisclosureSEC source: 0001298711-23-000002 · wf-form4_167278944683523.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,707,901 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F3 · price: The transaction was executed in multiple trades ranging from $81.0000 to $81.2000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 23:44 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 7,484 | $80.30 | $600,956.97 |
DisclosureSEC source: 0001298711-23-000002 · wf-form4_167278944683523.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,708,429 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.9100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,572 | $80.10 | $846,816.14 |
DisclosureSEC source: 0001298711-22-000012 · wf-form4_167157500372068.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,777,146 F3 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F2 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.4300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F5 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the reporting person. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:23 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,527 | $80.10 | $843,169.54 |
DisclosureSEC source: 0001298711-22-000012 · wf-form4_167157500372068.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,715,913 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.4300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 23:26 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4 | $80.01 | $320.04 |
DisclosureSEC source: 0001298711-22-000009 · wf-form4_166967795016299.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,787,718 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F2 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F3 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:05 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 966 | $80.05 | $77,330.52 |
DisclosureSEC source: 0001298711-22-000007 · wf-form4_166811790955499.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,787,722 F3 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F4 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F2 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.1900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F5 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:05 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 823 | $80.04 | $65,870.70 |
DisclosureSEC source: 0001298711-22-000007 · wf-form4_166811790955499.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,726,440 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.1900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:59 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,854 | $82.19 | $234,575.68 |
DisclosureSEC source: 0001298711-22-000005 · wf-form4_166007877158506.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,788,688 F5 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F10 · price: The transaction was executed in multiple trades ranging from $82.0100 to $82.7300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the reporting person. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:59 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 13,058 | $81.61 | $1,065,638.57 |
DisclosureSEC source: 0001298711-22-000005 · wf-form4_166007877158506.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,791,542 F5 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F9 · price: The transaction was executed in multiple trades ranging from $81.0100 to $82.0000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the reporting person. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:59 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 9,088 | $80.24 | $729,208.40 |
DisclosureSEC source: 0001298711-22-000005 · wf-form4_166007877158506.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,804,600 F5 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish Krishnan. The Rule 10b5-1 trading plan adopted by the Reporting Person's spouse started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F6 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish Krishnan. F7 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.9700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the reporting person. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:59 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,576 | $82.20 | $211,754.93 |
DisclosureSEC source: 0001298711-22-000005 · wf-form4_166007877158506.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,727,263 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F4 · price: The transaction was executed in multiple trades ranging from $82.0200 to $82.8200. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:59 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 13,432 | $81.62 | $1,096,315.81 |
DisclosureSEC source: 0001298711-22-000005 · wf-form4_166007877158506.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,729,839 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F3 · price: The transaction was executed in multiple trades ranging from $81.0200 to $82.0100. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:59 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 8,992 | $80.22 | $721,331.95 |
DisclosureSEC source: 0001298711-22-000005 · wf-form4_166007877158506.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,743,271 F1 · kind: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on July 15, 2022 and will terminate on July 15, 2023 and contemplates quarterly sales of 25,000 shares with a limit price of $80.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $80.0000 to $80.9600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 02:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $63.55 | $0.00 |
DisclosureSEC source: 0001298711-22-000003 · wf-form4_164618760010701.xml · derivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-02-28 F5 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 28, 2023. Read SEC document |
| February 26, 2022 Filed Mar 2, 2022 02:20 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 3,282 | $62.50 | $205,125.00 |
DisclosureSEC source: 0001298711-22-000003 · wf-form4_164618760010701.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,752,263 F1 · shares: Represents tax withholding upon the vesting of 7,100 shares of restricted stock on February 26, 2022. F2 · price: The closing price on February 25, 2022 of the Company's common stock on NASDAQ. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 100,000 | $70.50 | $7,050,000.00 |
DisclosureSEC source: 0000899243-21-048125 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 50,000 F1 · shares: On December 3, 2021, Krystal Biotech, Inc. (the "Company"), closed the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a public offering price of $75.00 per share. The Company and certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 400,000 shares of the Company's common stock offered in the public offering, which includes up to 200,000 shares from the selling stockholders. The underwriters exercised the option and on December 10, 2021, purchased the 400,000 shares of the Company's common stock, including 100,000 shares of the Company's common stock from the Krishnan Family Trust, a selling stockholder. F2 · ownership.nature: Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. F3 · ownership.nature: Prior to the reported transaction, the Krishnan Family Trust held 112,162 shares. In connection with the reported transaction, 18,919 shares were transferred to the Krishnan Family Trust from the reporting person's individual account and 18,919 shares were transferred to the Krishnan Family Trust from Krish Krishnan's, the reporting person's spouse, individual account. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:42 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 42,600 | $0.00 Strike: $78.89 | $0.00 |
DisclosureSEC source: 0000899243-21-009168 · doc4.xml · derivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,600 Underlying: Common Stock · 42,600 shares Expires 2025-02-26 F4 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 26, 2022. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:42 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantCommon Stock | 28,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-009168 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,864,464 F1 · security: Award of restricted stock which vests in four equal annual installments beginning on February 26, 2022. F1 · shares: Award of restricted stock which vests in four equal annual installments beginning on February 26, 2022. F1 · price: Award of restricted stock which vests in four equal annual installments beginning on February 26, 2022. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 22:35 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,126 | $47.29 | $53,248.31 |
DisclosureSEC source: 0000899243-20-025576 · doc4.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,836,064 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. The Rule 10b5-1 trading plan has now expired. F8 · price: This transaction was executed in multiple trades ranging from $47.27 to $47.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 22:35 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 7,437 | $46.63 | $346,813.34 |
DisclosureSEC source: 0000899243-20-025576 · doc4.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,837,190 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. The Rule 10b5-1 trading plan has now expired. F7 · price: This transaction was executed in multiple trades ranging from $46.27 to $47.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 22:35 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,594 | $46.09 | $488,296.53 |
DisclosureSEC source: 0000899243-20-025576 · doc4.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,844,627 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. The Rule 10b5-1 trading plan has now expired. F6 · price: This transaction was executed in multiple trades ranging from $45.27 to $46.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.